Skip to content

Ironwood seeing STARS as $1B bet hits in phase 3—and triggers 30% stock drop – Fierce Biotech

Ironwood seeing STARS as $1B bet hits in phase 3—and triggers 30% stock drop – Fierce Biotech

 

 Ironwood Pharmaceuticals’ $1 billion short bowel syndrome (SBS) bet has delivered a phase 3 win—and wiped 30% off the company’s share price. While the study met its primary endpoint, the results failed to convince investors it can win out over Takeda’s Gattex, its potential… 

Read More